Seasonal variation and temporal relationship to the COVID-19 pandemic of NMDA receptor antibody results.

"Declarations Conflicts of interestJPR reports research funding from the Wellcome Trust, royalties from Taylor & Francis, payment for reviewing from Johns Hopkins University Press and speaker fees from the Alberta Psychiatric Association and Infomed Research and Training Ltd. MSZ declares honoraria for one lecture each for each of the four mentioned in the last 4 years: Norwegian Neurological Society; Copenhagen Neuropsychological Society, Rigshospitalet; Cygnet Healthcare; and UCB Pharma. MSZ declares travel and hotel support for a stay in Florence from the European Association of Neurology (EAN) for an EAN meeting on autoimmune encephalitis in April 2022. MSZ represents neurology in the UK for the Association of British Neurologists for matters related to COVID in meetings with NHS England and Royal College of Physicians. SJ has served as an international advisory board member for Alexion, Alnylam, ArgenX, Immunovant, Janssen, Regeneron and UCB pharmaceuticals, is currently an expert panel member of Myasthenia Gravis consortium for Argenx pharmaceuticals, and has received speaker fees from Terumo BCT and Eisai pharmaceuticals. MSH declares salary support to support research time from the NIHR UCLH BRC. The other authors report no potential conflict of interest. Ethical standardThis study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments. As the study was a service evaluation and audit using anonymised patient records, informed consent was not required. Conflicts of interest JPR reports research funding from the Wellcome Trust, royalties from Taylor & Francis, payment for reviewing from Johns Hopkins University Press and speaker fees from the Alberta Psychiatric Association and Infomed Research and Training Ltd. MSZ declares honoraria for one lecture each for each of the four mentioned in the last 4 years: Norwegian Neurological Society; Copenhagen Neuropsychological Society, Rigshospitalet; Cygnet Healthcare; and UCB Pharma. MSZ declares travel and hotel support for a stay in Florence from the European Association of Neurology (EAN) for an EAN meeting on autoimmune encephalitis in April 2022. MSZ represents neurology in the UK for the Association of British Neurologists for matters related to COVID in meetings with NHS England and Royal College of Physicians. SJ has served as an international advisory board member for Alexion, Alnylam, ArgenX, Immunovant, Janssen, Regeneron and UCB pharmaceuticals, is currently an expert panel member of Myasthenia Gravis consortium for Argenx pharmaceuticals, and has received speaker fees from Terumo BCT and Eisai pharmaceuticals. MSH declares salary support to support research time from the NIHR UCLH BRC. The other authors report no potential conflict of interest."

"Funding JPR is supported by the Wellcome Trust (220659/Z/20/Z). TP was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. ME is supported by Action Medical Research (GN2835) and the British Paediatric Neurology Association. MK is supported by the Wellcome Trust (222907/Z/21/Z). MSH, ASD, and GL are supported by the NIHR UCLH BRC. GL is supported by the Wellcome Trust and NIHR."